Global Retinal Biologics Market
Global Retinal Biologics Market

Retinal Biologics Comprehensive Study by Application (Hospitals, Clinics, Research Organizations, Others), Diagnostic Tests (Amsler grid test, Optical coherence tomography (OCT), Fundus autofluorescence (FAF), Others), Disease Indication (Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Epiretinal Membrane, Macular Hole, Other) Players and Region - Global Market Outlook to 2026

Retinal Biologics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 206 Pages 175 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Retinal Biologics Market Overview:
Biologics are effective medicines made up of small components such as sugars, proteins, or DNA, or entire cells or tissues. Retinal biologics are bioengineered particles implanted in the eyes to treat chronic retinal diseases. The majority of biologics are derived from living organisms, such as plant or animal cells or microorganisms. Macugen, Humira, Lucentis, Eylea, and other retinal biologics are used to treat retinal diseases. With the increase in diabetes across the world; the demand for retinal biologics is also increasing. Some of the players profiled in the study are Spark Therapeutics (United States), Regeneron Pharmaceuticals, Inc. (United States), AbbVie Inc. (United States), Johnson & Johnson (United States), Amgen Inc. (United States), Novartis International AG (Switzerland), ALLERGAN (Ireland), Janssen Biotech (United States), Ocular Therapeutix (United States), Samsung Biologics (South Korea) and Spark Therapeutics (United States).

On the basis of geography, the market of Retinal Biologics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnostic Tests, the sub-segment i.e. Amsler grid test will boost the Retinal Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indication, the sub-segment i.e. Retinal Tear will boost the Retinal Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Need of Retinal Biologics to Treat Retinal Diseases
  • Growing Diabetic Population

Influencing Trend
  • Advancements in Technology of Retinal Biologics

Restraints
  • High Cost Associated with Retinal Biologics

Opportunities
  • Increasing Awareness About the Retinal Disease Will Boost the Demand of Retinal Biologics
  • Growing Investment in Medical Infrastructure by Developing Countries Will Increase the Demand of Retinal Biologics

Challenges
  • Need of High R&D Expenses for The Development of Retinal Biologics
  • Lack of Enough Skilled Employees to Operate in Manufacture of Retinal Biologics


Key Market Developments:


On 24th Feb 2014, The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.'s supplementary Biologics LicenInjection for the treatment of Macular Edema after Branch Retinal Vein Occlusion for standard review (BRVO). The goal for a regular review of a sBLA under the Prescription Drug User Fee Act (PDUFA) is ten months from application.

Target Audience:
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Retinal Biologics Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Retinal Biologics market on the basis of product [] , application [Hospitals, Clinics, Research Organizations and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Retinal Biologics market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Retinal Biologics industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Retinal Biologics market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Clinics
  • Research Organizations
  • Others
By Diagnostic Tests
  • Amsler grid test
  • Optical coherence tomography (OCT)
  • Fundus autofluorescence (FAF)
  • Others

By Disease Indication
  • Retinal Tear
  • Retinal Detachment
  • Diabetic Retinopathy
  • Epiretinal Membrane
  • Macular Hole
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Need of Retinal Biologics to Treat Retinal Diseases
      • 3.2.2. Growing Diabetic Population
    • 3.3. Market Challenges
      • 3.3.1. Need of High R&D Expenses for The Development of Retinal Biologics
      • 3.3.2. Lack of Enough Skilled Employees to Operate in Manufacture of Retinal Biologics
    • 3.4. Market Trends
      • 3.4.1. Advancements in Technology of Retinal Biologics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Retinal Biologics, by Application, Diagnostic Tests, Disease Indication and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Retinal Biologics (Value)
      • 5.2.1. Global Retinal Biologics by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Research Organizations
        • 5.2.1.4. Others
      • 5.2.2. Global Retinal Biologics by: Diagnostic Tests (Value)
        • 5.2.2.1. Amsler grid test
        • 5.2.2.2. Optical coherence tomography (OCT)
        • 5.2.2.3. Fundus autofluorescence (FAF)
        • 5.2.2.4. Others
      • 5.2.3. Global Retinal Biologics by: Disease Indication (Value)
        • 5.2.3.1. Retinal Tear
        • 5.2.3.2. Retinal Detachment
        • 5.2.3.3. Diabetic Retinopathy
        • 5.2.3.4. Epiretinal Membrane
        • 5.2.3.5. Macular Hole
        • 5.2.3.6. Other
      • 5.2.4. Global Retinal Biologics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Retinal Biologics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Spark Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ALLERGAN (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Janssen Biotech (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ocular Therapeutix (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Samsung Biologics (South Korea)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Spark Therapeutics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Retinal Biologics Sale, by Application, Diagnostic Tests, Disease Indication and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Retinal Biologics (Value)
      • 7.2.1. Global Retinal Biologics by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Research Organizations
        • 7.2.1.4. Others
      • 7.2.2. Global Retinal Biologics by: Diagnostic Tests (Value)
        • 7.2.2.1. Amsler grid test
        • 7.2.2.2. Optical coherence tomography (OCT)
        • 7.2.2.3. Fundus autofluorescence (FAF)
        • 7.2.2.4. Others
      • 7.2.3. Global Retinal Biologics by: Disease Indication (Value)
        • 7.2.3.1. Retinal Tear
        • 7.2.3.2. Retinal Detachment
        • 7.2.3.3. Diabetic Retinopathy
        • 7.2.3.4. Epiretinal Membrane
        • 7.2.3.5. Macular Hole
        • 7.2.3.6. Other
      • 7.2.4. Global Retinal Biologics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Retinal Biologics: by Application(USD Million)
  • Table 2. Retinal Biologics Hospitals , by Region USD Million (2015-2020)
  • Table 3. Retinal Biologics Clinics , by Region USD Million (2015-2020)
  • Table 4. Retinal Biologics Research Organizations , by Region USD Million (2015-2020)
  • Table 5. Retinal Biologics Others , by Region USD Million (2015-2020)
  • Table 6. Retinal Biologics: by Diagnostic Tests(USD Million)
  • Table 7. Retinal Biologics Amsler grid test , by Region USD Million (2015-2020)
  • Table 8. Retinal Biologics Optical coherence tomography (OCT) , by Region USD Million (2015-2020)
  • Table 9. Retinal Biologics Fundus autofluorescence (FAF) , by Region USD Million (2015-2020)
  • Table 10. Retinal Biologics Others , by Region USD Million (2015-2020)
  • Table 11. Retinal Biologics: by Disease Indication(USD Million)
  • Table 12. Retinal Biologics Retinal Tear , by Region USD Million (2015-2020)
  • Table 13. Retinal Biologics Retinal Detachment , by Region USD Million (2015-2020)
  • Table 14. Retinal Biologics Diabetic Retinopathy , by Region USD Million (2015-2020)
  • Table 15. Retinal Biologics Epiretinal Membrane , by Region USD Million (2015-2020)
  • Table 16. Retinal Biologics Macular Hole , by Region USD Million (2015-2020)
  • Table 17. Retinal Biologics Other , by Region USD Million (2015-2020)
  • Table 18. South America Retinal Biologics, by Country USD Million (2015-2020)
  • Table 19. South America Retinal Biologics, by Application USD Million (2015-2020)
  • Table 20. South America Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 21. South America Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 22. Brazil Retinal Biologics, by Application USD Million (2015-2020)
  • Table 23. Brazil Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 24. Brazil Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 25. Argentina Retinal Biologics, by Application USD Million (2015-2020)
  • Table 26. Argentina Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 27. Argentina Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 28. Rest of South America Retinal Biologics, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 30. Rest of South America Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 31. Asia Pacific Retinal Biologics, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Retinal Biologics, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 34. Asia Pacific Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 35. China Retinal Biologics, by Application USD Million (2015-2020)
  • Table 36. China Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 37. China Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 38. Japan Retinal Biologics, by Application USD Million (2015-2020)
  • Table 39. Japan Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 40. Japan Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 41. India Retinal Biologics, by Application USD Million (2015-2020)
  • Table 42. India Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 43. India Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 44. South Korea Retinal Biologics, by Application USD Million (2015-2020)
  • Table 45. South Korea Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 46. South Korea Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 47. Taiwan Retinal Biologics, by Application USD Million (2015-2020)
  • Table 48. Taiwan Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 49. Taiwan Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 50. Australia Retinal Biologics, by Application USD Million (2015-2020)
  • Table 51. Australia Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 52. Australia Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Retinal Biologics, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 56. Europe Retinal Biologics, by Country USD Million (2015-2020)
  • Table 57. Europe Retinal Biologics, by Application USD Million (2015-2020)
  • Table 58. Europe Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 59. Europe Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 60. Germany Retinal Biologics, by Application USD Million (2015-2020)
  • Table 61. Germany Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 62. Germany Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 63. France Retinal Biologics, by Application USD Million (2015-2020)
  • Table 64. France Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 65. France Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 66. Italy Retinal Biologics, by Application USD Million (2015-2020)
  • Table 67. Italy Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 68. Italy Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 69. United Kingdom Retinal Biologics, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 71. United Kingdom Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 72. Netherlands Retinal Biologics, by Application USD Million (2015-2020)
  • Table 73. Netherlands Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 74. Netherlands Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 75. Rest of Europe Retinal Biologics, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 77. Rest of Europe Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 78. MEA Retinal Biologics, by Country USD Million (2015-2020)
  • Table 79. MEA Retinal Biologics, by Application USD Million (2015-2020)
  • Table 80. MEA Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 81. MEA Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 82. Middle East Retinal Biologics, by Application USD Million (2015-2020)
  • Table 83. Middle East Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 84. Middle East Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 85. Africa Retinal Biologics, by Application USD Million (2015-2020)
  • Table 86. Africa Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 87. Africa Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 88. North America Retinal Biologics, by Country USD Million (2015-2020)
  • Table 89. North America Retinal Biologics, by Application USD Million (2015-2020)
  • Table 90. North America Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 91. North America Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 92. United States Retinal Biologics, by Application USD Million (2015-2020)
  • Table 93. United States Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 94. United States Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 95. Canada Retinal Biologics, by Application USD Million (2015-2020)
  • Table 96. Canada Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 97. Canada Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 98. Mexico Retinal Biologics, by Application USD Million (2015-2020)
  • Table 99. Mexico Retinal Biologics, by Diagnostic Tests USD Million (2015-2020)
  • Table 100. Mexico Retinal Biologics, by Disease Indication USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Retinal Biologics: by Application(USD Million)
  • Table 113. Retinal Biologics Hospitals , by Region USD Million (2021-2026)
  • Table 114. Retinal Biologics Clinics , by Region USD Million (2021-2026)
  • Table 115. Retinal Biologics Research Organizations , by Region USD Million (2021-2026)
  • Table 116. Retinal Biologics Others , by Region USD Million (2021-2026)
  • Table 117. Retinal Biologics: by Diagnostic Tests(USD Million)
  • Table 118. Retinal Biologics Amsler grid test , by Region USD Million (2021-2026)
  • Table 119. Retinal Biologics Optical coherence tomography (OCT) , by Region USD Million (2021-2026)
  • Table 120. Retinal Biologics Fundus autofluorescence (FAF) , by Region USD Million (2021-2026)
  • Table 121. Retinal Biologics Others , by Region USD Million (2021-2026)
  • Table 122. Retinal Biologics: by Disease Indication(USD Million)
  • Table 123. Retinal Biologics Retinal Tear , by Region USD Million (2021-2026)
  • Table 124. Retinal Biologics Retinal Detachment , by Region USD Million (2021-2026)
  • Table 125. Retinal Biologics Diabetic Retinopathy , by Region USD Million (2021-2026)
  • Table 126. Retinal Biologics Epiretinal Membrane , by Region USD Million (2021-2026)
  • Table 127. Retinal Biologics Macular Hole , by Region USD Million (2021-2026)
  • Table 128. Retinal Biologics Other , by Region USD Million (2021-2026)
  • Table 129. South America Retinal Biologics, by Country USD Million (2021-2026)
  • Table 130. South America Retinal Biologics, by Application USD Million (2021-2026)
  • Table 131. South America Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 132. South America Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 133. Brazil Retinal Biologics, by Application USD Million (2021-2026)
  • Table 134. Brazil Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 135. Brazil Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 136. Argentina Retinal Biologics, by Application USD Million (2021-2026)
  • Table 137. Argentina Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 138. Argentina Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 139. Rest of South America Retinal Biologics, by Application USD Million (2021-2026)
  • Table 140. Rest of South America Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 141. Rest of South America Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 142. Asia Pacific Retinal Biologics, by Country USD Million (2021-2026)
  • Table 143. Asia Pacific Retinal Biologics, by Application USD Million (2021-2026)
  • Table 144. Asia Pacific Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 145. Asia Pacific Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 146. China Retinal Biologics, by Application USD Million (2021-2026)
  • Table 147. China Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 148. China Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 149. Japan Retinal Biologics, by Application USD Million (2021-2026)
  • Table 150. Japan Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 151. Japan Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 152. India Retinal Biologics, by Application USD Million (2021-2026)
  • Table 153. India Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 154. India Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 155. South Korea Retinal Biologics, by Application USD Million (2021-2026)
  • Table 156. South Korea Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 157. South Korea Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 158. Taiwan Retinal Biologics, by Application USD Million (2021-2026)
  • Table 159. Taiwan Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 160. Taiwan Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 161. Australia Retinal Biologics, by Application USD Million (2021-2026)
  • Table 162. Australia Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 163. Australia Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Retinal Biologics, by Application USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 166. Rest of Asia-Pacific Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 167. Europe Retinal Biologics, by Country USD Million (2021-2026)
  • Table 168. Europe Retinal Biologics, by Application USD Million (2021-2026)
  • Table 169. Europe Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 170. Europe Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 171. Germany Retinal Biologics, by Application USD Million (2021-2026)
  • Table 172. Germany Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 173. Germany Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 174. France Retinal Biologics, by Application USD Million (2021-2026)
  • Table 175. France Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 176. France Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 177. Italy Retinal Biologics, by Application USD Million (2021-2026)
  • Table 178. Italy Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 179. Italy Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 180. United Kingdom Retinal Biologics, by Application USD Million (2021-2026)
  • Table 181. United Kingdom Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 182. United Kingdom Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 183. Netherlands Retinal Biologics, by Application USD Million (2021-2026)
  • Table 184. Netherlands Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 185. Netherlands Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 186. Rest of Europe Retinal Biologics, by Application USD Million (2021-2026)
  • Table 187. Rest of Europe Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 188. Rest of Europe Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 189. MEA Retinal Biologics, by Country USD Million (2021-2026)
  • Table 190. MEA Retinal Biologics, by Application USD Million (2021-2026)
  • Table 191. MEA Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 192. MEA Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 193. Middle East Retinal Biologics, by Application USD Million (2021-2026)
  • Table 194. Middle East Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 195. Middle East Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 196. Africa Retinal Biologics, by Application USD Million (2021-2026)
  • Table 197. Africa Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 198. Africa Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 199. North America Retinal Biologics, by Country USD Million (2021-2026)
  • Table 200. North America Retinal Biologics, by Application USD Million (2021-2026)
  • Table 201. North America Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 202. North America Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 203. United States Retinal Biologics, by Application USD Million (2021-2026)
  • Table 204. United States Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 205. United States Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 206. Canada Retinal Biologics, by Application USD Million (2021-2026)
  • Table 207. Canada Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 208. Canada Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 209. Mexico Retinal Biologics, by Application USD Million (2021-2026)
  • Table 210. Mexico Retinal Biologics, by Diagnostic Tests USD Million (2021-2026)
  • Table 211. Mexico Retinal Biologics, by Disease Indication USD Million (2021-2026)
  • Table 212. Research Programs/Design for This Report
  • Table 213. Key Data Information from Secondary Sources
  • Table 214. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Retinal Biologics: by Application USD Million (2015-2020)
  • Figure 5. Global Retinal Biologics: by Diagnostic Tests USD Million (2015-2020)
  • Figure 6. Global Retinal Biologics: by Disease Indication USD Million (2015-2020)
  • Figure 7. South America Retinal Biologics Share (%), by Country
  • Figure 8. Asia Pacific Retinal Biologics Share (%), by Country
  • Figure 9. Europe Retinal Biologics Share (%), by Country
  • Figure 10. MEA Retinal Biologics Share (%), by Country
  • Figure 11. North America Retinal Biologics Share (%), by Country
  • Figure 12. Global Retinal Biologics share by Players 2020 (%)
  • Figure 13. Global Retinal Biologics share by Players (Top 3) 2020(%)
  • Figure 14. Global Retinal Biologics share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Spark Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 17. Spark Therapeutics (United States) Revenue: by Geography 2020
  • Figure 18. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 20. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 23. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 24. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. ALLERGAN (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. ALLERGAN (Ireland) Revenue: by Geography 2020
  • Figure 30. Janssen Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 31. Janssen Biotech (United States) Revenue: by Geography 2020
  • Figure 32. Ocular Therapeutix (United States) Revenue, Net Income and Gross profit
  • Figure 33. Ocular Therapeutix (United States) Revenue: by Geography 2020
  • Figure 34. Samsung Biologics (South Korea) Revenue, Net Income and Gross profit
  • Figure 35. Samsung Biologics (South Korea) Revenue: by Geography 2020
  • Figure 36. Spark Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 37. Spark Therapeutics (United States) Revenue: by Geography 2020
  • Figure 38. Global Retinal Biologics: by Application USD Million (2021-2026)
  • Figure 39. Global Retinal Biologics: by Diagnostic Tests USD Million (2021-2026)
  • Figure 40. Global Retinal Biologics: by Disease Indication USD Million (2021-2026)
  • Figure 41. South America Retinal Biologics Share (%), by Country
  • Figure 42. Asia Pacific Retinal Biologics Share (%), by Country
  • Figure 43. Europe Retinal Biologics Share (%), by Country
  • Figure 44. MEA Retinal Biologics Share (%), by Country
  • Figure 45. North America Retinal Biologics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Spark Therapeutics (United States)
  • Regeneron Pharmaceuticals, Inc. (United States)
  • AbbVie Inc. (United States)
  • Johnson & Johnson (United States)
  • Amgen Inc. (United States)
  • Novartis International AG (Switzerland)
  • ALLERGAN (Ireland)
  • Janssen Biotech (United States)
  • Ocular Therapeutix (United States)
  • Samsung Biologics (South Korea)
  • Spark Therapeutics (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation